RAC

1.27%

$1.55 race oncology ltd

Medical / Clinical Discussions, page-497

First 497 Last

Share
Profile

Follow
KingBuzzo

357 Posts.

808

17/06/21

14:01

Post #: 53900636
Share

Originally posted by RaceOncology: ↑

1. Yes this “repatenting" strategy has been used before - a good example of this is CPX-351 (Vyxeos) which is just two old generic drugs (doxorubicin and ara-c) in a liposome. This was sold to Jazz for around US$2 billion.

2. Yes this is correct and is one of the major reasons we continue to spend resources on developing and patenting new IP around manufacturing, formulation and use. Of course it is possible that someone will work around our patents, but in someways this is self defeating. As a pharma company you want exclusivity, not a price war. What can prevent this from even being considered as an option is orphan drug designation.

3. Orphan drug designation provides 7 years post approval (i.e. after you start selling) exclusivity (even if you have no patent what so ever) in the USA and 10 years in the EU. By pursuing a rapid path to approval in an orphan indication (AML) we can head off anyone even attempting to try and work around our patents as they would be locked out of selling the drug for 7 to 10 years. If you couldn’t sell a drug for 10 years why would you expend money and effort on trying to make Bisantrene?

Ultimately I see the competition coming from completely new FTO inhibitors. The real value of Bisantrene is the huge amount of clinical data (and manufacturing) we have that gives us a jump on all the new FTO inhibitors that will be developed. Just like was seen with Keytruda, being first can give you a really strong market position even when faced with lots of competition (there are now 7 different anti-PD-1/PD-L1 drugs on the market). Keyruda doesn’t sell $10s of billion a year because it is the only choice, but because clinicians are familiar with it.

Expand

Thanks again for your quick response. It's very reassuring that there's a solid strategy that can be summarized so succinctly. I assumed this was the case of course, but just couldn't find all the pieces at the time...

RAC Price at posting: $3.71 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Bitcoin: Current State of Play & Where to Next | Swyftx

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Emerald & Azure score Digger & Dealer awards

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

There are more pages in this discussion • 2 more messages in this thread...

First 497 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.55		Change -0.020(1.27%)		Mkt cap ! $264.0M

Open	High	Low	Value	Volume
$1.59	$1.62	$1.51	$218.3K	138.7K

Buyers (Bids)

No.	Vol.	Price($)
1	95	$1.53

Sellers (Offers)

Price($)	Vol.	No.
$1.55	157	1

View Market Depth

No.	Vol.	Price($)
3	29100	1.500
1	353	1.470
2	3444	1.440
3	101000	1.420
4	14785	1.400

Price($)	Vol.	No.
1.550	157	1
1.580	6715	2
1.600	2319	1
1.620	5327	1
1.630	1270	1

Last trade - 16.10pm 16/08/2024 (20 minute delay)

RAC (ASX) Chart

Medical / Clinical Discussions, page-497

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Bitcoin: Current State of Play & Where to Next | Swyftx

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Emerald & Azure score Digger & Dealer awards

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Medical / Clinical Discussions, page-497

Top Stories

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Bitcoin: Current State of Play & Where to Next | Swyftx

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Emerald & Azure score Digger & Dealer awards

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News